camrelizumab
jiangsu hengrui pharmaceuticals
['esophageal', 'camrelizumab']
attending #asco22? supplement your schedule with escort-1st trial: camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma, from 
Home of @JAMA_Current, @JAMANetworkOpen, @JAMAHealthForum, & 10 specialty journals that publish science and opinion shaping #medicine today and into the future.